The three most common cardiovascular risk tools are largely inaccurate in patients with inflammatory arthritis and, surprisingly, osteoarthritis.
Researchers utilized the UK Clinical Practice Research Datalink to identify patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS).
Used patients with osteoarthritis (OA) — a noninflammatory condition — as the control
Calculated 10-year cardiovascular risk using QRISK-3, the Framingham Risk Score, and Reynolds Risk Score for patients
Compared observed and predicted risk in each disease group
Both the Framingham Risk Score and Reynolds Risk Score underpredicted risk across all disease categories while QRISK-3 overpredicted risk.
The tools also underperformed in predicting risk in osteoarthritis patients.
QRISK-3 and Framingham more accurately predicted risk in patients with AS versus those with RA, PsA, and OA.
There is a need for more specific CVD risk prediction tools for rheumatic conditions.
David Hughes, PhD, of the University of Liverpool, UK, led the research. Co-author Sizheng Steven Zhao, MBChB, PhD, of the University of Manchester, UK, presented abstract OP0267 on June 2 at the European Alliance of Associations for Rheumatology (EULAR) 2023 Annual Meeting.
Researchers used coded data and the analysis did not include mortality data.
The study was funded by a grant from the Psoriasis and Psoriatic Arthritis Alliance (PAPAA).
Source: Read Full Article